SCHEMBL6700908

SCHEMBL6700908

COc1ccc(CNC(=O)c2ccc3ccn(CCOc4ccccc4)c(=O)c3c2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 5/20 0.55
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
TP53 P04637 4/20 0.47
POLB P06746 2/20 0.47
LMNA P02545 2/20 0.47
ALDH1A1 P00352 3/20 0.47
KDM4E B2RXH2 2/20 0.47
CYP2C9 P11712 2/20 0.47
HPGD P15428 2/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C19 P33261 1/20 0.47
PTPN7 P35236 1/20 0.47
DRD2 P14416 1/20 0.47
HPGDS O60760 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
SLC22A8 Q8TCC7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6699591 0.92 KDM4E (0.54) MMP13NPC1RAB9ATP53POLB
SCHEMBL2116432 0.85 HDAC6 (0.56) MMP13MEN1KMT2ANPC1RAB9A
SCHEMBL2118644 0.82 HDAC6 (0.46) MEN1KMT2AALDH1A1CYP2C9HPGD
SCHEMBL2120728 0.82 MAPK1 (0.53) MEN1KMT2ANPC1RAB9APOLB
SCHEMBL6703820 0.82 MAPK1 (0.56) MEN1KMT2ANPC1RAB9APOLB
SCHEMBL6702695 0.80 MEN1 (0.48) MEN1KMT2APOLBALDH1A1CYP2C9
SCHEMBL6698476 0.80 MMP13 (0.60) MMP13TP53POLBLMNAALDH1A1
SCHEMBL2116350 0.80 HDAC6 (0.55) MMP13MEN1KMT2ANPC1RAB9A
SCHEMBL2619344 0.79 SMPD1 (0.50) MEN1KMT2AALDH1A1CYP2C9HPGD
SCHEMBL10268001 0.79 HDAC6 (0.51)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040044000-A1 Isoquinoline derivatives as matrix metalloproteinase inhibitors BUNKER AMY MAE (US) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044000-A1 Isoquinoline derivatives as matrix metalloproteinase inhibitors MMP1, MMP13, MMP9 MMP13 2/4885MEN1 3092/4885KMT2A 2967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.